The Impact of the Covid-19 Pandemic on New and Ongoing Clinical Trials
Navigating the COVID-19 Pandemic, Preparing for the Rest of 2020 & Planning a Return to "Normalcy" in the New Clinical Trial Landscape

Name: The Impact of the Covid-19 Pandemic on New and Ongoing Clinical Trials
Start: 2020-06-25
End: 2020-06-26

June 25 - 26, 2020 | Virtual Event

View Program

Vendor Registration

Free End User Registration

The first half of 2020 has significantly impacted the clinical trial landscape. As clinical trial hosts, sites and management leaders continue to navigate the impact of the ongoing pandemic, convene in a virtually interactive environment with other life science leaders to:

Gain FDA guidance in real-time for new and ongoing trials, and take part in an interactive Q&A to discuss due diligence, compliance and preparation for what comes next
Identify opportunities for enhanced patient engagement presented by the post-Covid19 trial environment
Hear best practices from pioneers in telehealth and how to avoid the pitfalls when integrating it into your future trial design
Understand the risk and what needs to be in place before diving into remote, digital trial models and e health solutions
Take part in an interactive virtual experience and convene with key decision makers in clinical trial design, strategy and operations as they discuss challenges facing the industry and how to overcome them

View Program

Featured Speakers

Len Rosenberg PhD, RPh

Head, Clinical Operations

Beat AML/LLS

Leslie Jebson

Executive Director, Clinical Strategy

Texas A&M Health

Diane Maloney

Associate Director Policy, Center for Biologics Evaluation and Research (CBER)

Food and Drug Administration (FDA)

Rose Gerber

Director of Patient Advocacy and Education

Community Oncology Alliance (COA)

Jennifer Healey

Head of Global Medical Operations

Sanofi

Jeff Douglas

Head of Clinical Operations

MyoKardia

Craig Lipset

Assistant Professor of Health Informatics

Rutgers University

Steffen Thirstrup MD, PhD

Fmr. Head of Division, Medicines Assessment and Clinical Trials

Danish Health and Medicines Authority

Heiner Gertzen

Head GxP Inspection & Audit Readiness

Sanofi

Tim Hagerty

VP Development & Business Operations

Dantari

View All Speakers

What makes us different

LIVE event. No pre-recorded sessions

Social: Real-time Q&A between speakers and attendees during sessions, live polling, and direct messaging capability between attendees

Enhanced Networking: automated matchmaking suggestions based on your goals & interests. Use our digital platform “meeting rooms” and set up 1:1 meetings.